Navigation Links
Hospira Reports Second-Quarter 2011 Results
Date:7/27/2011

p>43.0%Income from Operations

17.9%

12.0%19.9%

22.0%Results under U.S. Generally Accepted Accounting Principles (GAAP) include items as detailed in the schedules attached to this press release.

Net sales increased 9.9 percent to $1.1 billion in the second quarter of 2011, compared to $968 million in the second quarter of 2010. Driving the quarter's performance was strong sales in Specialty Injectable Pharmaceuticals, primarily driven by U.S. sales of the oncolytic docetaxel, as well as by contribution from several other newer compounds.

Adjusted* income from operations decreased 0.5 percent to $212 million in the second quarter of 2011, compared to $213 million in the second quarter of 2010. The decrease is primarily due to a difficult year-over-year comparison driven by strong margin contribution from U.S. sales of oncolytic oxaliplatin in the second quarter of 2010, as well as the 2011 impact of the joint-venture arrangement related to the production of docetaxel, which tempered the margin contribution of U.S. docetaxel sales.

The effective tax rate on an adjusted basis* in the quarter was 23.0 percent, a slight decrease from the second-quarter 2010 rate of 23.8 percent.

Cash Flow Cash flow from operations for the first six months of 2011 was $253 million, compared to the $144 million generated for the same period in 2010. The increase primarily reflects the timing of rebate and chargeback payments, partially offset by higher inventory levels.

Capital expenditures were $139 million for the first six months of 2011, compared to $79 million for the first six months of 2010. The increase is related to the company's capacity expansion and information technology (IT) initiatives.

During the second quarter, Hospira entered into accelerated share repurchase (ASR) agreements under its $1 billion share repurchase authorization. Under the agreements, which the company completed in July 2011, the company re
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Hospira to Host Conference Call for Second-Quarter 2011 Results
2. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
3. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
4. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
5. Hospira Reports First-Quarter 2011 Results
6. Hospira Board Authorizes $1 Billion Share Repurchase Program
7. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
8. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
9. Hospira to Host Conference Call for First-Quarter 2011 Results
10. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
11. Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- People with the ... condition called peripheral artery disease (PAD), a new study suggests. ... supply blood to the limbs, most often the legs. The ... narrowing of the arteries throughout the body. People with PAD ... Researchers analyzed data from nearly 6,800 people with PAD who ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... News) -- U.S. health officials have concluded that it,s ... anthrax during a safety mishap last month. But, ... have announced a moratorium on the transfer of any ... In a report issued Friday, the CDC outlined several ... similar incident doesn,t occur again. Last month, as many ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... kids is almost a nightmare to their respective parents, ... Researchers identified three factors that may increase a child's ... the disease that does not respond to commonly used ... before their first birthday which is also called symptomatic ...
... Female sexual dysfunction is associated with loss of libido, ... who have attained their menopause or whose ovaries had ... serve as an effective treatment in such sexual dysfunction, ... meeting of the American Urological Association in Anaheim, California. ...
... to improve sexual function among the hypertensive men with ... is the disease process itself, probably from reduced vascular ... a study evaluated hypertensive men with erectile dysfunction and ... 7.3% before losartan therapy to 58.5 % after losartan ...
... the current New England Journal of Medicine that an experimental ... men suffering from hemophilia. This method shows signs of ... clotting protein they lack. None of the patients suffers ... ,The study was designed only to test the safety and ...
... high doses of vitamin E may help fight diabetes. ... the world with many ravaging complications, affecting millions of ... damage, kidney failure, non healing ulcers all over the ... system. ,Diabetes is caused by the deficiency of ...
... latest mantra of Pfizer. The pharmaceutical giant has announced ... hardest hit by the AIDS virus. The decision by the ... Government winning a landmark case against pharmaceutical companies. In ... Diflucan will be given free of cost to battle HIV ...
Cached Medicine News:
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... OraQuick is an FDA approved ... whole blood test used to ... HIV-1 infection. This CLIA waived ... of antibodies to HIV-1, requires ...
... is designed to detect the IgM ... whole blood. The QuickVue+ Infectious Mononucleosis ... erythrocytes which give a greater sensitivity ... from sheep and horse erythrocytes. QuickVue+ ...
... point-of-care diagnostic test that can reliably and ... and B. The test uses a unique ... assists viral replication by promoting the release ... ZstatFlu substrate is labeled with a chromagen. ...
Medicine Products: